Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors

Human Gene Therapy

Volumn 18, Issue 7, 2007, Pages 627-641

  Hakkarainen, Tanja ^a,b   Sarkioja, Merja ^a,b   Lehenkari, Petri ^c   Miettinen, Susanna ^d   Ylikomi, Timo ^d,e   Suuronen, Riitta ^d   Desmond, Renee A ^f   Kanerva, Anna ^a,b   Hemminki, Akseli ^a,b,g  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF OULU   (Finland)

^d TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^e TAMPERE UNIVERSITY HOSPITAL   (Finland)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTEGRIN; CD51 ANTIGEN; ONCOLYTIC ADENOVIRUS; PROTEOHEPARAN SULFATE;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOAVAILABILITY; BONE MARROW; BREAST CANCER; CANCER GRAFT; CONTROLLED STUDY; FEMALE; GENE TARGETING; HUMAN; HUMAN CELL; LUNG CANCER; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; TISSUE DISTRIBUTION; TUMOR XENOGRAFT; VIRUS INFECTIVITY; VIRUS REPLICATION; WILD TYPE;

ADENOVIRIDAE; ANIMALS; BREAST NEOPLASMS; CELL SURVIVAL; CELLS, CULTURED; FEMALE; GENE THERAPY; HUMANS; LUNG NEOPLASMS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MICE; MICE, NUDE; ONCOLYTIC VIROTHERAPY; TRANSDUCTION, GENETIC; TROPISM; VIRUS REPLICATION;

ADENOVIRIDAE; MIRIDAE; MURINAE;

EID: 34547543191     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2007.034     Document Type: Article

References (57)

1. AGGARWAL, S., and PITTENGER, M.F. (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105, 1815-1822.
2. ALEMANY, R., SUZUKI, K., and CURIEL, D.T. (2000). Blood clearance rates of adenovirus type 5 in mice. J. Gen. Virol. 81, 2605-2609.
3. AMADO, L.C., SALIARIS, A.P., SCHULERI, K.H., ST JOHN, M., XIE, J.S., CATTANEO, S., DURAND, D.J., FITTON, T., KUANG, J.Q., STEWART, G., LEHRKE, S., BAUMGARTNER, W.W., MARTIN, B.J., HELDMAN, A.W., and HARE, J.M. (2005). Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc. Natl. Acad. Sci. U.S.A. 102, 11474-11479.
4. BAUERSCHMITZ, G.J., BARKER, S.D., and HEMMINKI, A. (2002). Adenoviral gene therapy for cancer: From vectors to targeted and replication competent agents [review]. Int. J. Oncol. 21, 1161-1174.
5. BAUERSCHMITZ, G.J., GUSE, K., KANERVA, A., MENZEL, A., HERRMANN, I., DESMOND, R.A., YAMAMOTO, M., NETTELBECK, D.M., HAKKARAINEN, T., DALL, P., CURIEL, D.T., and HEMMINKI, A. (2006). Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells. Mol. Ther. 14, 164-174.
6. BESSIS, N., GARCIACOZAR, F.J., and BOISSIER, M.C. (2004). Immune responses to gene therapy vectors: Influence on vector function and effector mechanisms. Gene Ther. 11(Suppl. 1), S10-S17.
7. CHAMBERLAIN, J.R., SCHWARZE, U., WANG, P.R., HIRATA, R.K., HANKENSON, K.D., PACE, J.M., UNDERWOOD, R.A., SONG, K.M., SUSSMAN, M., BYERS, P.H., and RUSSELL, D.W. (2004). Gene targeting in stem cells from individuals with osteogenesis imperfecta. Science 303, 1198-1201.
8. CONGET, P.A., and MINGUELL, J.J. (2000). Adenoviral-mediated gene transfer into ex vivo expanded human bone marrow mesenchymal progenitor cells. Exp. Hematol. 28, 382-390.
9. DMITRIEV, I., KRASNYKH, V., MILLER, C.R., WANG, M., KASHENTSEVA, E., MIKHEEVA, G., BELOUSOVA, N., and CURIEL, D.T. (1998). An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J. Virol. 72, 9706-9713.
10. DVORAK, H.F. (1986). Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 315, 1650-1659.
11. FUEYO, J., GOMEZ-MANZANO, C., ALEMANY, R., LEE, P.S., McDONNELL, T.J., MITLIANGA, P., SHI, Y.X., LEVIN, V.A., YUNG, W.K., and KYRITSIS, A.P. (2000). A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19, 2-12.
12. GAGGAR, A., SHAYAKHMETOV, D.M., and LIEBER, A. (2003). CD46 is a cellular receptor for group B adenoviruses. Nat. Med. 9, 1408-1412.
13. GOODISON, S., VIARS, C., and URQUIDI, V. (2005). Molecular cytogenetic analysis of a human breast metastasis model: Identification of phenotype-specific chromosomal rearrangements. Cancer Genet. Cytogenet. 156, 37-48.
14. GUSE, K., DIAS, J.D., BAUERSCHMITZ, G.J., HAKKARAINEN, T., AAVIK, E., RANKI, T., PISTO, T., SARKIOJA, M., DESMOND, R.A., KANERVA, A., and HEMMINKI, A. (2007). Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo. Gene Ther. 14, 902-911.
15. HARVEY, B.-G., HACKETT, N.R., EL-SAWY, T., ROSENGART, T.K., HIRSCHOWITZ, E.A., LIEBERMAN, M.D., LESSER, M.L., and CRYSTAL, R.G. (1999). Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs. J. Virol. 73, 6729-6742.
16. HEISE, C., HERMISTON, T., JOHNSON, L., BROOKS, G., SAMPSON-JOHANNES, A., WILLIAMS, A., HAWKINS, L., and KIRN, D. (2000). An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat. Med. 6, 1134-1139.
17. HEMMINKI, A., DMITRIEV, I., LIU, B., DESMOND, R.A., ALEMANY, R., and CURIEL, D.T. (2001). Targeting oncolytic adenoviral agents to the epidermal growth factor pathway with a secretory fusion molecule. Cancer Res. 61, 6377-6381.
18. IZADPANAH, R., TRYGG, C., PATEL, B., KRIEDT, C., DUFOUR, J., GIMBLE, J.M., and BUNNELL, B.A. (2006). Biologic properties of mesenchymal stem cells derived from bone marrow and adipose tissue. J. Cell Biochem. 99, 1285-1297.
19. JOKI, T., MACHLUF, M., ATALA, A., ZHU, J., SEYFRIED, N.T., DUNN, I.F., ABE, T., CARROLL, R.S., and BLACK, P.M. (2001). Continuous release of endostatin from microencapsulated engineered cells for tumor therapy. Nat. Biotechnol. 19, 35-39.
20. KANERVA, A., MIKHEEVA, G.V., KRASNYKH, V., COOLIDGE, C.J., LAM, J.T., MAHASRESHTI, P.J., BARKER, S.D., STRAUGHN, M., BARNES, M.N., ALVAREZ, R.D., HEMMINKI, A., and CURIEL, D.T. (2002). Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin. Cancer Res. 8, 275-280.
21. KANERVA, A., ZINN, K.R., CHAUDHURI, T.R., LAM, J.T., SUZUKI, K., UIL, T.G., HAKKARAINEN, T., BAUERSCHMITZ, G.J., WANG, M., LIU, B., CAO, Z., ALVAREZ, R.D., CURIEL, D.T., and HEMMINKI, A. (2003). Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol. Ther. 8, 449-458.
22. KERN, S., EICHLER, H., STOEVE, J., KLUTER, H., and BIEBACK, K. (2006). Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 24, 1294-1301.
23. KNAAN-SHANZER, S., VAN DE WATERING, M.J.M., VAN DER VELDE, I., GONCALVES, M.A.F.V., VALERIO, D., and DE VRIES, A.A.F. (2005). Endowing human adenovirus serotype 5 vectors with fiber domains of species B greatly enhances gene transfer into human mesenchymal stem cells. Stem Cells 23, 1598-1607.
24. KOMAROVA, S., KAWAKAMI, Y., STOFF-KHALILI, M.A., CURIEL, D.T., and PEREBOEVA, L. (2006). Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol. Cancer Ther. 5, 755-766.
25. KUHNEL, F., SCHULTE, B., WIRTH, T., WOLLER, N., SCHAFERS, S., ZENDER, L., MANNS, M., and KUBICKA, S. (2004). Protein transduction domains fused to virus receptors improve cellular virus uptake and enhance oncolysis by tumor-specific replicating vectors. J. Virol. 78, 13743-13754.
26. LAW, L.K., and DAVIDSON, B.L. (2005). What does it take to bind CAR? Mol. Ther. 12, 599-609.
27. LE BLANC, K., RASMUSSON, I., SUNDBERG, B., GOTHERSTROM, C., HASSAN, M., UZUNEL, M., and RINGDEN, O. (2004). Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363, 1439-1441.
28. LESKELA, H.V., RISTELI, J., NISKANEN, S., KOIVUNEN, J., IVASKA, K.K., and LEHENKARI, P. (2003). Osteoblast recruitment from stem cells does not decrease by age at late adulthood. Biochem. Biophys. Res. Commun. 311, 1008-1013.
29. LI, Y., PONG, R.C., BERGELSON, J.M., HALL, M.C., SAGALOWSKY, A.I., TSENG, C.P., WANG, Z., and HSIEH, J.T. (1999). Loss of adenoviral receptor expression in human bladder cancer cells: A potential impact on the efficacy of gene therapy. Cancer Res. 59, 325-330.
30. LU, L., ZHAO, C., LIU, Y., SUN, X., DUAN, C., JI, M., ZHAO, H., XU, Q., and YANG, H. (2005). Therapeutic benefit of TH-engineered mesenchymal stem cells for Parkinson's disease. Brain Res. Brain Res. Protoc. 15, 46-51.
31. MIYAHARA, Y., NAGAYA, N., KATAOKA, M., YANAGAWA, B., TANAKA, K., HAO, H., ISHINO, K., ISHIDA, H., SHIMIZU, T., KANGAWA, K., SANO, S., OKANO, T., KITAMURA, S., and MORI, H. (2006). Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction. Nat. Med. 12, 459-465.
32. MIZUGUCHI, H., SASAKI, T., KAWABATA, K., SAKURAI, F., and HAYAKAWA, T. (2005). Fiber-modified adenovirus vectors mediate efficient gene transfer into undifferentiated and adipogenic-differentiated human mesenchymal stem cells. Biochem. Biophys Res. Commun. 332, 1101-1106.
33. NAKAMIZO, A., MARINI, F., AMANO, T., KHAN, A., STUDENY, M., GUMIN, J., CHEN, J., HENTSCHEL, S., VECIL, G., DEMBINSKI, J., ANDREEFF, M., and LANG, F.F. (2005). Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res. 65, 3307-3318.
34. NAKAMURA, K., ITO, Y., KAWANO, Y., KUROZUMI, K., KOBUNE, M., TSUDA, H., BIZEN, A., HONMOU, O., NIITSU, Y., and HAMADA, H. (2004). Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther. 11, 1155-1164.
35. NETTELBECK, D.M., RIVERA, A.A., BALAGUE, C., ALEMANY, R., and CURIEL, D.T. (2002). Novel oncolytic adenoviruses targeted to melanoma: Specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. Cancer Res. 62, 4663-4670.
36. OLMSTED-DAVIS, E.A., GUGALA, Z., GANNON, F.H., YOTNDA, P., McALHANY, R.E., LINDSEY, R.W., and DAVIS, A.R. (2002). Use of a chimeric adenovirus vector enhances BMP2 production and bone formation. Hum. Gene Ther. 13, 1337-1347.
37. PARKER, A.L., WADDINGTON, S.N., NICOL, C.G., SHAYAKHMETOV, D.M., BUCKLEY, S.M., DENBY, L., KEMBALL-COOK, G., NI, S., LIEBER, A., McVEY, J.H., NICKLIN, S.A., and BAKER, A.H. (2006). Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood 108, 2554-2561.
38. PEREBOEVA, L., KOMAROVA, S., MIKHEEVA, G., KRASNYKH, V., and CURIEL, D.T. (2003). Approaches to utilize mesenchymal progenitor cells as cellular vehicles. Stem Cells 21, 389-404.
39. PROCKOP, D.J. (1997). Marrow stromal cells as stem cells for non-hematopoietic tissues. Science 276, 71-74.
40. RAKI, M., REIN, D.T., KANERVA, A., and HEMMINKI, A. (2006). Gene transfer approaches for gynecological diseases. Mol. Ther. 14, 154-163.
41. RANKI, T., KANERVA, A., RISTIMAKI, A., HAKKARAINEN, T., SARKIOJA, M., KANGASNIEMI, L., RAKI, M., LAAKKONEN, P., GOODISON, S., and HEMMINKI, A. (2007a). A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Δ24, for the treatment of advanced breast cancer. Gene Ther, 14, 58-67.
42. RANKI, T., SARKIOJA, M., HAKKARAINEN, T., SMITTEN, K., KANERVA, A., and HEMMINKI, A. (2007b). Systemic efficacy of oncolytic adenoviruses in imagable orthotopic models of hormone refractory metastatic breast cancer. Int. J. Cancer 121, 2919-2928.
43. REDDY, P.S., GANESH, S., and YU, D.-C. (2006). Enhanced gene transfer and oncolysis of head and neck cancer and melanoma cells by fiber chimeric oncolytic adenoviruses. Clin. Cancer Res. 12, 2869-2878.
44. RUSSELL, W.C. (2000). Update on adenovirus and its vectors. J. Gen. Virol. 81, 2573-2604.
45. SANDMAIR, A.M., LOIMAS, S., PURANEN, P., IMMONEN, A., KOSSILA, M., PURANEN, M., HURSKAINEN, H., TYYNELA, K., TURUNEN, M., VANNINEN, R., LEHTOLAINEN, P., PALJARVI, L., JOHANSSON, R., VAPALAHTI, M., and YLA-HERTTUALA, S. (2000). Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum. Gene Ther. 11, 2197-2205.
46. SÄRKIOJA, M., KANERVA, A., SALO, J., KANGASNIEMI, L., ERIKSSON, M., RAKI, M., RANKI, T., HAKKARAINEN, T., and HEMMINKI, A. (2006). Noninvasive imaging for evaluation of the systemic delivery of capsid-modified adenoviruses in an orthotopic model of advanced lung cancer. Cancer 107, 1578-1588.
47. SAVELKOUL, H.F., VAN OMMEN, R., VOSSEN, A.C., BREEDLAND, E.G., COFFMAN, R.L., and VAN OUDENAREN, A. (1994). Modulation of systemic cytokine levels by implantation of alginate encapsulated cells. J. Immunol. Methods 170, 185-196.
48. SHAYAKHMETOV, D.M., GAGGAR, A., NI, S., LI, Z.Y., and LIEBER, A. (2005). Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J. Virol. 79, 7478-7491.
49. SHEN, B.H., BAUZON, M., and HERMISTON, T.W. (2006). The effect of hypoxia on the uptake, replication and lytic potential of group B adenovirus type 3 (Ad3) and type 11p (Ad11p). Gene Ther. 13, 986-990.
50. SHERR, C.J. (1996). Cancer cell cycles. Science 274, 1672-1677.
51. SIRENA, D., LILIENFELD, B., EISENHUT, M., KALIN, S., BOUCKE, K., BEERLI, R.R., VOGT, L., RUEDL, C., BACHMANN, M.F., GREBER, U.F., and HEMMI, S. (2004). The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3. J. Virol. 78, 4454-4462.
52. STUDENY, M., MARINI, F.C., CHAMPLIN, R.E., ZOMPETTA, C., FIDLER, I.J., and ANDREEFF, M. (2002). Bone marrow-derived mesenchymal stem cells as vehicles for interferon-β delivery into tumors. Cancer Res. 62, 3603-3608.
53. STUDENY, M., MARINI, F.C., DEMBINSKI, J.L., ZOMPETTA, C., CABREIRA-HANSEN, M., BEKELE, B.N., CHAMPLIN, R.E., and ANDREEFF, M. (2004). Mesenchymal stem cells: Potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J. Natl. Cancer Inst. 96, 1593-1603.
54. SUZUKI, K., FUEYO, J., KRASNYKH, V., REYNOLDS, P.N., CURIEL, D.T., and ALEMANY, R. (2001). A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin. Cancer Res. 7, 120-126.
55. TALENS-VISCONTI, R., BONORA, A., JOVER, R., MIRABET, V., CARBONELL, F., CASTELL, J.V., and GOMEZ-LECHON, M.J. (2006). Hepatogenic differentiation of human mesenchymal stem cells from adipose tissue in comparison with bone marrow mesenchymal stem cells. World J. Gastroenterol. 12, 5834-5845.
56. TUVE, S., WANG, H., WARE, C., LIU, Y., GAGGAR, A., BERNT, K., SHAYAKHMETOV, D., LI, Z., STRAUSS, R., STONE, D., and LIEBER, A. (2006). A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells. J. Virol. 80, 12109-12120.
57. WU, H., SEKI, T., DMITRIEV, I., UIL, T., KASHENTSEVA, E., HAN, T., and CURIEL, D.T. (2002). Double modification of adenovirus fiber with RGD and polylysine motifs improves coxsackievirus-adenovirus receptor-independent gene transfer efficiency. Hum. Gene Ther. 13, 1647-1653.